Sarcoma, Synovial
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)
Drugs by status
Approved for this indication (1)
Phase 3 trials (10)
Phase 2 trials (36)
- dexrazoxane
- atezolizumab
- sorafenib
- temsirolimus
- cixutumumab
- dehydroepiandrosterone
- vismodegib
- gemcitabine
- imatinib
- aldesleukin
- ramucirumab
- lorvotuzumab mertansine
- ixabepilone
- pembrolizumab
- ny-eso-1 reactive tcr retroviral vector transduced autologous pbl
- olaratumab
- ipilimumab
- reolysin
- ro4929097
- sapanisertib
- bevacizumab
- everolimus
- tazemetostat
- tgfbdnrii-transduced autologous tumor infiltrating lymphocytes
- zoledronic acid
- masct:multiple antigens specific cellular therapy
- docetaxel
- romidepsin
- interferon gamma-1b
- 9-ing-41
- +6 more
Phase 1 trials (28)
- anti-ny eso-1 tcr-transduced t cells
- autologous ny-eso-1-specific cd8-positive t lymphocytes
- rifampin
- id-lv305
- nivolumab
- itacitinib
- ribociclib
- ny-eso-1-specific t cells
- otsa101-dtpa-90y
- itraconazole
- autologous genetically modified mage a4c1032 t cells
- autologous genetically modified t cells, ny-eso-1c259 t
- Peposertib
- tumor-pulsed dendritic cells
- sargramostim
- tp-1287
- tcr-t cells
- ima203
- 4-1bbζ egfr806-egfrt
- 4 1bbζ cd19-her2tg
- otsa101-dtpa-111in
- 4-1bbζ b7h3-egfrt-dhfr
- 4-1bbζ cd19-her2tg
- fhd-609
- aoh1996
- pepticrad-1
- st316
- mrna-4203
Organizations
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (32)
- Adaptimmune
- Medarex
- Imclone
- Merck
- Eli Lilly
- Genentech
- Bayer
- GlaxoSmithKline
- Oncolytics Biotech
- Shenzhen BinDeBio Ltd.
- Takara Bio Inc.
- Epizyme, Inc.
- National Institutes of Health (NIH)
- Centre Leon Berard
- Cornell University
- Harvard University
- Temple University
- Ludwig Institute for Cancer Research
- Oregon Health and Science University
- Southwest Oncology Group
- University of Michigan
- University of Rochester
- Wake Forest University
- Zhengzhou University
- University of Calgary
- Cancer Immunotherapy Trials Network
- European Organisation for Research and Treatment of Cancer
- University of Texas at Houston
- State University of New York, Buffalo
- Maria Sklodowska Curie Children's Hospital
- +2 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (1)